Goldline Pharmaceutical Schedules Board Meeting to Approve Half-Year Results
Goldline Pharmaceutical Ltd 路 Intimation 路 14 Nov 2026, 5:30 am
Goldline Pharmaceutical Schedules Board Meeting to Approve Half-Year Results Goldline Pharmaceutical Limited announced that its Board of Directors will meet on 14th Nov'26 to consider and approve the standalone unaudited financial results for the half-year ended 30th Sep'26, alongside the statement of assets and liabilities. The meeting outcome will be disclosed following the board's conclusion.
Original exchange filing (PDF)
More announcements from Goldline Pharmaceutical Ltd
- Submission of statement of deviation and variation of the half year ended 30th september 2026 路 15 Nov 2026
- Declaration of Un-audited Standalone Financial Results of the company for the half year ended September 30, 2026 路 15 Nov 2026
- Outcome of Board Meeting dated 14th November, 2026 pursuant to Reg 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 & Submission .... 路 15 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Mujumdar 路 02 Sept 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Mujumdar 路 02 Sept 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Laxmikant Mujumdar 路 01 Sept 2026
- Scrutinizer Report 路 31 Aug 2026
- AGM Proceedings of the 22nd Annual General Meeting (AGM) of the Company pertaining to Financial Year 2025-26. 路 30 Aug 2026
